Company Overview:,, Portal Biotechnologies, headquartered in Watertown, MA, is a rapidly scaling cell-engineering platform company operating across three high-value business lines (biopharma R&D screening, next-generation cell therapy manufacturing, and AI training data generation), addressing markets totaling $100B+. Backed by $24M in venture funding and an $8M DARPA contract, Portal's proprietary mechanoporation technology enables efficient multiplex delivery of diverse cargos such as RNA, proteins, small molecules, and gene-editing tools without compromising cell function.